Introduction
============

Epidemiology studies have reported an association between increased ambient particle matter (PM) levels and hospital admission rates due to respiratory illnesses including asthma.[@b1-bii-3-2010-029] Diesel exhaust particles (DEP) are an important contributor to ambient PM and many studies have focused on DEP as a model anthropogenic pollutant. DEP consist of a carbon core surrounded by various amounts of adsorbed organic compounds, including polycyclic aromatic hydrocarbons (PAHs), quinones, and nitro-PAHs.[@b2-bii-3-2010-029] Human and rodent studies have shown that DEP augments the induction of allergic lung disease when given with an antigen.[@b3-bii-3-2010-029]--[@b6-bii-3-2010-029] Although the chemical composition and biologic mechanisms associated with the adjuvant effects of DEP are not well understood, the organic components of DEP and resulting oxidative stress responses are thought to skew the immune system towards a T-helper 2 (T~H~2) response.[@b7-bii-3-2010-029]--[@b10-bii-3-2010-029]

The composition of DEP varies greatly depending on the type of engine, load, and method of collection, which in turn can alter its biological function. Singh et al[@b8-bii-3-2010-029] investigated the chemical characteristics and pulmonary toxicity of two different particles, an automobile derived DEP (A-DEP) and National Institute of Standard Technology standard reference material 2975 (N-DEP) generated from a heavy forklift. The two particle samples exhibited disparate pulmonary toxicity and mutagenic activity, which reflected their dissimilar chemical composition. Recently, we assessed the effects of N-DEP, A-DEP, and a newer particle termed C-DEP (generated from a diesel engine used to power a compressor) in a murine ovalbumin (OVA) mucosal sensitization model.[@b11-bii-3-2010-029] These samples differed in their percentage of dichloromethane (DCM) extractable organic material (EOM) and PAHs with N-DEP, C-DEP, and A-DEP containing 1.5%, 18.9%, and 67% EOM, and 47, 431, and 522 μg of PAHs per gram of DEP, respectively. Immune and inflammatory endpoints demonstrated the degree of allergic adjuvancy as follows: C-DEP/OVA ≈ A-DEP/OVA \>\> N-DEP/OVA suggesting that the amount of PAHs rather than the total organic content tracked with adjuvant activity. Consistent with this strong degree of adjuvancy post-challenge, the C-DEP exposure at sensitization increased the influx of eosinophils, neutrophils, and lymphocytes, and the production of T~H~2 cytokines, while reducing levels of the T~H~1 cytokine IL-12 in the BALF.[@b11-bii-3-2010-029] In contrast, the elemental carbon rich N-DEP/OVA induced a milder T~H~2 phenotype post-sensitization while the A-DEP did not alter measured post-sensitization values, but displayed strong adjuvant activities post-challenge.[@b11-bii-3-2010-029]

We have previously demonstrated that inhalation exposure to fresh diesel exhaust (DE) from the same engine that produced the C-DEP sample at an occupationally relevant dose, caused mild adjuvant effects compared to air controls.[@b12-bii-3-2010-029] Global gene expression analysis showed that the DE in combination with OVA sensitization altered oxidative stress and metabolism pathways, whereas DE in the absence of immunization modulated cell cycle control, growth and differentiation, G-proteins, and cell adhesion pathways. To understand more precisely which pathways and cellular signaling events were amplified by the three chemically distinct DEP samples during sensitization, we initiated a similar global genomic approach. Microarray analysis of whole-lung RNA was used to elucidate the pathways and networks involved in the effects of N-DEP, A-DEP, and C-DEP with or without allergen sensitization in BALB/C mice. The design of the study permitted direct comparison of early global gene expression changes with the previously reported pulmonary immune and inflammatory effects of DEP alone and in combination with OVA.

Materials and Methods
=====================

Animals
-------

Female BALB/C mice (8--10 weeks old) were obtained from Charles River Laboratories (Raleigh, NC) and allowed to acclimate for a minimum of one week prior to dosing. Mice were randomly assigned to treatment groups and housed in an AAALAC-approved animal facility at the US-EPA. All animal procedures were reviewed and approved by the US-EPA's Institutional Animal Care and Use Committee. Housing environment conditions include a 12-h light/dark cycle at an ambient temperature of 22 ± 1 °C and relative humidity of 55 ± 5 °C. Mice were provided water and mouse chow *ad libitum*. Additional mice from each facility were routinely monitored serologically for Sendai, mouse pneumonia, mouse hepatitis, and other murine viruses, as well as mycoplasma.

Particle samples
----------------

Standard Reference Material (SRM) 2975 diesel exhaust particle sample (N-DEP) was purchased from National Institute of Standard Technology (NIST) (Gaithersburg, MD). The reported mean diameter of these particles was 11.2 ± 0.1 μm by area distribution, and the surface area, as determined by nitrogen adsorption, was 91 μm^2^/g. The certified analysis contains 11 certified concentrations and 28 reference concentrations for selected PAHs found in the DEPs. The DEP was generated by a heavy-duty forklift diesel engine and collected under "hot" conditions without a dilution tunnel.

Automobile DEP (A-DEP; courtesy of T. Kobayashi, NIES, Japan) was generated and collected under conditions previously described.[@b13-bii-3-2010-029],[@b14-bii-3-2010-029] Briefly, the sample was generated by a light-duty (2740 cc), 4-cylinder Isuzu diesel engine. DEP was collected under "cold" (50 °C) conditions onto glass-fiber filters and on steel duct walls in a constant-volume sampling system fitted at the end of a dilution tunnel.

Compressor DEP (C-DEP) was generated in-house as described by Cao et al[@b15-bii-3-2010-029] at the EPA using a 30 kW (40 hp) 4-cylinder Deutz BF4M1008 diesel engine connected to a 22.3 kW Saylor Bell air compressor to provide 20% load. The generated particles were collected under "hot" conditions in a baghouse.

Experimental design
-------------------

DEP samples (N-, C-, A-DEP) were suspended at a concentration of 3 mg/ml in saline alone or with 0.4 mg/ml of OVA. Particles were sonicated using a Microson Ultrasonic Cell Disruptor (Micromix) for 10 min. Mice were randomly divided into 8 treatment groups containing 5 mice each, anesthetized with isofluorane, and exposed to saline, 20 μg OVA, 150 μg DEP, or DEP + OVA by intranasal instillation on Days 0 and 13 and necropsied 18 hrs later. Additional groups of animals were held for subsequent phenotypic analysis post-challenge.

Necropsy and RNA isolation
--------------------------

Mice were euthanized with sodium pentobarbital and bled by cardiac puncture. The chest wall was opened and the left lung lobe was removed, quick frozen in liquid nitrogen, and stored at −80 °C. RNA from frozen lung tissue was isolated using RNeasy (Qiagen, Valencia, CA) following manufacturer's protocol. Quantity and quality of the RNA was measured using a Nanospot and Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA), respectively. Three mice were randomly selected from each group of five animals for microarray analysis.

Microarray
----------

RNA samples were selected prepared, processed, and hybridized to the Affymetrix Mouse 430 A gene chip at Expression Analysis (Durham, NC), as described in the GeneChip Expression Analysis Manual (Affymetrix; Santa Clara, CA). The hybridized probe array was stained with streptavidin phycoerythrin conjugate and scanned by the GeneChip^®^ Scanner 3000 (Affymetrix; Santa Clara, CA). The amount of light emitted at 570 nm is proportional to the bound target at each location on the probe array.

The Mouse 430 A Genome chip contains over 22,000 probe sets representing over 14,000 well-characterized mouse genes. A detailed description can be found at <http://www.affymetrix.com/products/arrays/specific/mouse430.affx>. A total of 24 gene chips representing lung samples from 24 individual mice (8 treatments, N = 3) were used in this study. The microarray data have been deposited at Genome Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>) and are accessible through GEO series accession number GSE22357.

Overall data analysis strategy
------------------------------

The analysis approach of this data set, consisting of 2 controls and 6 treatment groups, was to use a binary comparison approach of each treatment group compared to its respective control: N-DEP and saline, A-DEP and saline, C-DEP and saline, N-DEP/OVA and OVA, A-DEP/OVA and OVA, and C-DEP/OVA and OVA. The analysis of these data sets consisted of: 1) evaluating the data quality; 2) performing principal components analysis (PCA) for a global inspection of within group sample correspondence and to examine model and dose effects; 3) performing Gene Set Enrichment Analysis (GSEA) to determine differentially expressed gene sets between a treatment group and its control; 4) extracting core genes responsible for a particular gene set identified as significant from the GSEA analysis; 5) determining common differentially expressed genes across treatment groups; 6) mapping core genes to functional pathways using KEGG pathways and MetaCore GENEGO^®^ to identify altered pathways and networks unique or in common among the treatments.

Principal component analysis (PCA)
----------------------------------

PCA transforms microarray data from all gene chips to a new coordinate system using an orthogonal linear transformation, which identifies a lower dimensional coordinate system that accounts for most of the variance in the data set. This analysis was employed to survey the data for within-group outliers and model and dose effects using Rosetta Resolver (Rosetta Inpharmatics, Agilent Technologies, Palo Alto, CA) following linear weighting normalization (*P* \< 0.001). Each individual gene chip or gene expression profile was represented by a single data point and the variance between a pair of gene chips was comparable to the distance between the data points. The closer the data points the greater the similarity of their gene expression profiles. This analysis was employed as a visual tool to initially inspect the data for within group and across group similarities and dissimilarities.

Gene set enrichment analysis (GSEA)
-----------------------------------

GSEA is a powerful computational method that utilizes an *a priori* defined set of genes to determine statistically significant, concordant differences between two phenotypes. For this analysis, probe-level data from 24 gene chips were imported into Gene Pattern ([www.genepattern.org](http://www.genepattern.org)) and preprocessed using the Robust Multichip Average (RMA) method, which uses background correction, quantile normalization, and median scaling to generate estimated expression summaries.[@b16-bii-3-2010-029] The RMA generated values were imported into GSEA to determine gene sets associated with each diesel treatment group compared to its respective control. The molecular signature database (MSigDB) C2 provided on the website <http://www.broad.mit.edu/gsea/msigdb/msigdbindex.html>, which contains 1687 gene sets, was queried for association with a particular treatment in each pairwise comparison (N-DEP/OVA and OVA, A-DEP/OVA and OVA, C-DEP/OVA and OVA, N-DEP and saline, A-DEP and saline, and C-DEP and saline). Only gene sets with a minimal gene set size of 15 genes per pathway and a maximum of 90 were queried. We acknowledge our use of GSEA software and MSigDB (<http://www.broad.mit.edu/gsea/>).[@b17-bii-3-2010-029]

Pathway level analysis
----------------------

The gene sets with a false discovery rate (FDR) q-value of \<0.01 were used to create a core gene list. The core gene list is comprised of genes responsible for a gene set being considered significant. These genes were exported and then applied to two pathway analysis programs, KEGG Pathway Analysis (<http://gather.genome.duke.edu/>) and MetaCore GENEGO^®^ (<http://www.genego.com/metacore>), which maps genes to pathways and determines pathway significance. All pathways with a *P*-value of \<0.001 and at least 5 or more differentially expressed genes were reported.

Results
=======

Principal component analysis (PCA)
----------------------------------

PCA was applied to provide a multidimensional gene expression profile of each gene chip in a 3 dimensional space to reveal clusters in the experimental data. All data from the 24 gene chips were analyzed with each dot representing a gene chip ([Fig. 1a](#f1-bii-3-2010-029){ref-type="fig"}). After analysis the gene chips were then highlighted in either blue (OVA treatment) or red (saline control). Good separation of the two groups was observed, illustrating a model effect between antigen and saline. The saline group appeared to be more tightly clustered than OVA indicating lower within group variability. To determine if exposure to chemically different DEP samples induces diverse genetic profiles, the gene chips were highlighted according to diesel sample (purple- A-DEP and A-DEP/OVA, blue- C-DEP and C-DEP/OVA, green- N-DEP and N-DEP/OVA, and yellow- saline and OVA) ([Fig. 1b](#f1-bii-3-2010-029){ref-type="fig"}). The plot revealed separation of the saline and OVA treated C-DEP and N-DEP groups, while the saline and OVA A-DEP exposed mice clustered together.

Gene set enrichment analysis (GSEA)
-----------------------------------

GSEA was developed to overcome the limitations of relatively small individual differential gene expression changes among biologically related genes and small sample size. In contrast to conventional microarray analysis programs, the algorithm employed by GSEA derives its power by focusing on gene sets with biological relevance rather than individual genes.[@b17-bii-3-2010-029],[@b18-bii-3-2010-029] To test for sets of related genes that were altered in the lungs of mice exposed to the various treatments, we employed GSEA. The arrays were separated into 6 binary groups; N-DEP/saline and saline, A-DEP/saline and saline, C-DEP/saline and saline, N-DEP/OVA and OVA, A-DEP/OVA and OVA, and C-DEP/OVA and OVA. The C2 collection of curated gene sets from the MSigDB were queried and a detailed description of each gene set can be found on the website <http://www.broad.mit.edu/gsea/msigdb/msigdb_zindex.html>. Gene sets with an FDR q-value of \<0.01 were considered significant. The number of significant gene sets associated with N-DEP, A-DEP, and C-DEP, as determined by the pairwise comparisons (DEP exposure and saline control), was 101, 90, and 98, respectively. In the context of antigen, 60, 68, and 113 gene sets were associated with N-, A-, and C-DEP/OVA, respectively. The complete list of the significant gene sets is found in [Appendices 1--6](#app1-bii-3-2010-029){ref-type="app"}.

Venn analyses
-------------

Venn analyses were performed to identify the common genes to all DEP exposures. The core genes (those genes responsible for a gene set being considered significant with an FDR q-values of \<0.01) were extracted from the significant gene sets associated with each diesel exposure identified by GSEA. A Venn diagram was constructed to identify genes common among the 3 DEP/saline exposure pairwise comparisons ([Fig. 2a](#f2-bii-3-2010-029){ref-type="fig"}). A-DEP/saline exposure resulted in the greatest number of differentially expressed genes (545). 200 genes were common among all 3 DEP treatments. Similarly a Venn diagram was constructed for the genes associated with each DEP/OVA exposure ([Fig. 2b](#f2-bii-3-2010-029){ref-type="fig"}). C-DEP/OVA exposure resulted in greatest number of differentially expressed genes (800). 236 genes were found common to all DEP/OVA exposures. The two sets of common genes were applied to another Venn diagram to identify the 117 common genes among all DEP exposures ([Fig. 2c](#f2-bii-3-2010-029){ref-type="fig"}).

KEGG pathway analyses
---------------------

To understand the biological significance of the common genes associated with the 3 DEP/saline exposures, the 200 genes were imported into the gene annotation tool, Gather (<http://gather.genome.duke.edu/>), and the genes were mapped to KEGG pathways, using the criteria that pathways must have 5 or more differentially expressed genes and be overrepresented based on a hypergeometric test with a *P*-value \<0.001. Cytokine-cytokine receptor interaction and toll-like receptor signaling pathways were common to all DEP/saline exposures ([Table 1](#t1-bii-3-2010-029){ref-type="table"}) with the majority of the genes being associated with neutrophil signaling. The 236 genes common among the 3 DEP/OVA exposures also significantly populated the cytokine-cytokine receptor interaction and toll-like receptor (TLR) signaling pathway ([Table 2](#t2-bii-3-2010-029){ref-type="table"}), but with better coverage of these pathways (40 and 17 genes for DEP/OVA versus 28 and 11 genes for DEP/saline, respectively). In addition the DEP/OVA treatments also significantly altered 11 genes associated with apoptosis pathways ([Table 2](#t2-bii-3-2010-029){ref-type="table"}).

To understand the effects of the individual DEP/OVA exposures, the extracted core genes were mapped to KEGG pathways and the results represented in [Tables 4](#t4-bii-3-2010-029){ref-type="table"}[](#t5-bii-3-2010-029){ref-type="table"}--[6](#t6-bii-3-2010-029){ref-type="table"}. All 3 exposures populated the cytokine-cytokine receptor pathway similarly with 56, 56, and 51 genes for N-DEP/OVA, A-DEP/OVA, and C-DEP/OVA, respectively. Additionally, the TLR pathway contained similar amounts of genes with 23, 26, and 28 genes for N-DEP/OVA, A-DEP/OVA, and C-DEP/OVA, respectively. This pathway contained TLRs as well as many pro-inflammatory cytokines and transcription factors. N-DEP/OVA and C-DEP/OVA altered the expression of genes in the neuroactive ligand-receptor interaction pathway. A-DEP/OVA and C-DEP/OVA also altered the apoptosis pathway, while additional pathways for pyrimidine metabolism and aminoacyl-tRNA biosynthesis were unique to the C-DEP/OVA exposures.

GeneGo analysis
---------------

The C-DEP/OVA exposure gave the highest transcriptional changes based on the numbers of signifi-cant gene sets, extracted core genes, and the KEGG pathways, however, these analyses were not specific enough to allow an inference as to why or how C-DEP was able to elicit a stronger T~H~2 response post-sensitization. We therefore mapped the 3 sets of genes to GeneGo curated databases and presented the results as networks and pathways. [Figure 3](#f3-bii-3-2010-029){ref-type="fig"} depicts the significance (−log(p)values) of the top 20 differentially affected GeneGo process networks for all 3 DEP/OVA exposures (N-DEP/OVA-blue; A-DEP/OVA-red; C-DEP/OVA-orange). Using this approach the similarities and differences of the groups can be clearly discerned. All groups significantly altered networks related to antigen presentation, inflammation, and cell adhesion. In addition the C-DEP/OVA exposure also altered networks related to cell cycle control, DNA damage, and protein degradation.

GeneGo pathway analysis revealed that the pathways common to all treatments were associated with MHC class I antigen presentation, inflammation, and other pathways related to the innate immune response. The A-DEP/OVA and C-DEP/OVA common pathways were involved with TNF-α mediated apoptosis pathways whereas C-DEP/OVA alone also induced altered expression of Fas, inhibitor of apoptosis (IAP), and mitochondrial mediated apoptosis and cell cycle regulation pathways ([Fig. 4](#f4-bii-3-2010-029){ref-type="fig"}).

Discussion
==========

DEP have been reported to act as adjuvants to upregulate immune responses resulting in increased allergic lung disease; however, there is still a lack of understanding as to what DEP component or components are responsible for these effects, and the underlying mechanisms through which they act. The present study examined global transcriptional changes in the lungs of mice after exposure to three chemically distinct DEP samples (N-, A- and C-DEP) with or without antigen sensitization. Overall, all the DEP and DEP/OVA samples significantly altered cytokine and TLR pathways compared to their respective controls, however, the DEP/OVA samples induced a greater number of genes in these pathways. In addition, A- and C-DEP/OVA samples altered apoptosis pathways while the most biologically active DEP sample, C-DEP/OVA, also altered cell cycle and DNA repair networks.

We recently reported the inflammatory and adjuvant effects of the above three diesels, N-, A-, and C-DEP.[@b11-bii-3-2010-029] Although it is important to identify individual genes associated with adverse biological effects, the resulting phenotypic changes likely occur through interactions of multiple genes. Therefore, to associate transcriptional responses with the allergic phenotype we utilized a global approach to a) characterize the genomic signature of DEP as a class and b) identify pathways common and unique to the DEP/OVA exposures.

Our genomic signature response to DEP as a class compound is well supported by the literature. DEP exposure has been shown to induce lung inflammation as manifested by neutrophil infiltration and elevated levels of total protein, albumin, LDH, and reactive oxygen species (ROS) in the lung as well as up-regulation of inflammatory cytokines.[@b3-bii-3-2010-029],[@b11-bii-3-2010-029],[@b12-bii-3-2010-029],[@b19-bii-3-2010-029],[@b20-bii-3-2010-029] Furthermore, DEP and other particles including ambient PM have been shown to induce TLR4 expression in the lung,[@b21-bii-3-2010-029],[@b22-bii-3-2010-029] while TLR4 deficient mice developed less airway inflammation in response to DEP compared to wild type controls.[@b23-bii-3-2010-029] In agreement with these findings, our results demonstrated the cytokine-cytokine receptor and the TLR interaction KEGG pathways were significantly altered in all DEP/saline exposures. These findings not only provide further evidence for the TLR pathway involvement in DEP induced inflammatory response, but also confirmed a common genomic signature response of DEP, regardless of chemical composition.

It has been established that while DEP alone can induce an inflammatory response, when given with an antigen they also act as an immunologic adjuvant.[@b3-bii-3-2010-029]--[@b6-bii-3-2010-029] The DEP/OVA exposures did not alter KEGG pathways such as antigen processing and presentation or T cell receptor signaling. Instead, in a similar fashion to DEP alone, genomic analysis of all the DEP/OVA exposed samples displayed common alterations in the cytokine-cytokine receptor and TLR KEGG pathways. This is a likely response because under this analysis all DEP/OVA samples were compared to OVA exposure. However, compared to DEP/saline, DEP/OVA exposed samples showed a more pronounced increase in the number of genes enriched in these pathways. This provides further evidence, on the genomic level, that DEP and OVA interacted synergistically to produce an immunomodulatory effect.

Li et al[@b24-bii-3-2010-029] proposed a hierarchical oxidative stress model to explain DEP induced effects whereby low levels of oxidative stress induce antioxidant defense mechanisms to restore redox balance in the cell (tier 1). Intermediate levels of oxidative stress (tier 2) activate MAPK and NF-κB cascades, which induce inflammation, while high levels of oxidative stress (tier 3) activate apoptosis and apoptosis/necrosis pathways.[@b24-bii-3-2010-029] In agreement with this model, the study presented here demonstrates similar effects *in vivo.* Antioxidant transcription factors and enzymes such as Nrf2, heme oxygenase 1 (HO-1), and superoxide dismutase 2 (SOD2) were up-regulated in response to all three DEP/OVA exposures, indicative of low levels of oxidative stress (tier 1). The tier 2 responses, MAPKs, NF-κB, as well as inflammatory, T~H~1, and T~H~2 cytokines and chemokines, were also up-regulated in all three DEP/OVA exposures. In addition, A- and C-DEP/OVA exposures altered apoptosis (tier 3) pathways with C-DEP/OVA having altered the greatest number of these pathways. From this analysis it would appear that these early changes were predictive of the previously reported post-challenge phenotype.[@b11-bii-3-2010-029]

It has been established that DEP organic compounds can generate ROS[@b25-bii-3-2010-029] and excessive ROS production can lead to a variety of cellular responses including DNA damage.[@b26-bii-3-2010-029] In fact, oxidative DNA damage (8-hydroxydeoxyguanosine) has been detected in mouse lung DNA after DEP exposure.[@b27-bii-3-2010-029] Although the A-DEP sample contained the greatest amount of DCM EOM, C-DEP contained the greatest amount of PAHs[@b11-bii-3-2010-029] and the C-DEP/OVA exposure group was unique in significantly altering cell cycle and DNA damage pathways. Global transcriptional analysis of lung tissue revealed up-regulation of cell cycle control genes including 6 cyclin genes, 7 cell division cycle genes, 7 members of the family of MAP kinases, 2 cyclin-dependent kinases, RAS p21 protein activator 3 (Rasa3), and 5 other RAS related proteins. Although we can not say with certainty that these changes were due to the PAH content, this evidence suggests the newer C-DEP sample generated more oxidative damage.

Conclusion
==========

In conclusion, mice exposed to all three DEP samples with or without OVA had altered cytokine and toll-like receptor pathways suggesting these responses are common to all DEPs regardless of chemical profile. All DEP/OVA exposures increased transcription of genes involved in tier 1 and 2 of the hierarchical stress response model described by Li et al.[@b24-bii-3-2010-029],[@b28-bii-3-2010-029],[@b29-bii-3-2010-029] Additionally, A- and C-DEP/OVA exposures significantly altered the most number of apoptosis pathways (tier 3). The C-DEP/OVA also altered cell cycle and DNA damage pathways suggesting it is the most bioactive sample. While the C-DEP sample also contained the largest amount of PAHs, these studies were not designed to address whether these components were causal to the effect. Nevertheless, it is known that PAHs can induce a proallergic effect.[@b30-bii-3-2010-029]--[@b32-bii-3-2010-029] This comprehensive approach using gene expression analysis to examine pathway changes at a transcriptional level provides a clearer picture of the events occurring in the lung after DEP exposure in the presence or absence of antigen. The results illustrate a wide range of altered pathways suggesting this method may be more sensitive and can be used for identifying mechanisms involved in induction of immune responses that lead to increased severity of allergic lung disease.

Funding
=======

The project described was supported by the EPA-UNC Curriculum in Toxicology Training agreement (\# T829472). This paper has been reviewed by the National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, and approved for publication. Approval does not signify that the contents necessarily reflect the views and policies of the Agency, nor does the mention of trade names or commercial products constitute endorsement or recommendation for use.

This article is available from <http://www.la-press.com>.

**Disclosures**

This manuscript has been read and approved by all authors. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The authors and peer reviewers of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material.

Dr. William Ward for review of the manuscript and helpful suggestions.

###### 

Significantly altered gene sets by N-DEP/saline compared to saline.

  Name                                      Sise   ES     NES    FDR q-val
  ----------------------------------------- ------ ------ ------ ------------
  CARIES_PULP_HIGH_UP                       68     0.81   2.85   \<1.00E-06
  LAL_KO_3MO_UP                             46     0.84   2.80   \<1.00E-06
  FLECHNER_KIDNEY_TRANSPLANT_REJECTION_UP   72     0.78   2.79   \<1.00E-06
  LINDSTEDT_DEND_8H_VS_48H_UP               58     0.81   2.78   \<1.00E-06
  LAL_KO_6MO_UP                             58     0.80   2.75   \<1.00E-06
  WIELAND_HEPATITIS_B\_INDUCED              71     0.77   2.71   \<1.00E-06
  GALINDO_ACT_UP                            75     0.74   2.66   \<1.00E-06
  YANG_OSTECLASTS_SIG                       39     0.84   2.61   \<1.00E-06
  NAKAJIMA_MCS_UP                           85     0.70   2.55   \<1.00E-06
  BLEO_HUMAN_LYMPH_HIGH_24HRS_UP            86     0.69   2.54   \<1.00E-06
  BASSO_GERMINAL_CENTER_CD40_UP             82     0.69   2.54   \<1.00E-06
  HINATA_NFKB_UP                            89     0.69   2.52   \<1.00E-06
  NADLER_OBESITY_UP                         57     0.73   2.51   \<1.00E-06
  SANA_TNFA_ENDOTHELIAL_UP                  61     0.72   2.50   \<1.00E-06
  NEMETH_TNF_UP                             82     0.69   2.49   \<1.00E-06
  MUNSHI_MM_VS_PCS_UP                       64     0.67   2.34   \<1.00E-06
  MUNSHI_MM_UP                              57     0.69   2.34   7.18E-05
  NI2_MOUSE_UP                              40     0.74   2.33   6.78E-05
  TNFA_NFKB_DEP_UP                          17     0.86   2.33   6.43E-05
  SHIPP_FL_VS_DLBCL_DN                      30     0.74   2.24   6.11E-05
  LINDSTEDT_DEND_UP                         44     0.69   2.23   5.81E-05
  TAVOR_CEBP_UP                             42     0.69   2.22   5.55E-05
  HOUSTIS_ROS                               32     0.73   2.21   5.31E-05
  MARTINELLI_IFNS_DIFF                      16     0.83   2.19   5.09E-05
  ZUCCHI_EPITHELIAL_DN                      36     0.68   2.19   4.88E-05
  TPA_SENS_MIDDLE_UP                        55     0.64   2.17   1.39E-04
  ROSS_CBF_MYH                              38     0.70   2.17   2.21E-04
  CROONQUIST_IL6_RAS_UP                     18     0.81   2.15   2.99E-04
  ZHAN_MULTIPLE_MYELOMA_VS_NORMAL_DN        33     0.71   2.15   2.89E-04
  NAKAJIMA_MCSMBP_MAST                      37     0.69   2.14   3.19E-04
  ABBUD_LIF_UP                              45     0.66   2.14   3.09E-04
  KNUDSEN_PMNS_UP                           65     0.62   2.14   2.99E-04
  JECHLINGER_EMT_UP                         56     0.63   2.12   4.73E-04
  DAC_BLADDER_UP                            23     0.76   2.12   4.59E-04
  DAC_IFN_BLADDER_UP                        16     0.82   2.12   4.46E-04
  PEART_HISTONE_DN                          63     0.61   2.11   4.34E-04
  RADAEVA_IFNA_UP                           38     0.67   2.10   4.22E-04
  ZELLER_MYC_UP                             23     0.73   2.10   4.11E-04
  CANCER_UNDIFFERENTIATED_META_UP           62     0.61   2.10   4.62E-04
  MARSHALL_SPLEEN_BAL                       25     0.74   2.09   4.50E-04
  PROTEASOMEPATHWAY                         21     0.73   2.09   4.69E-04
  TNFALPHA_ALL_UP                           66     0.59   2.08   5.41E-04
  EMT_UP                                    55     0.60   2.08   5.29E-04
  SCHUMACHER_MYC_UP                         47     0.63   2.07   5.17E-04
  PASSERINI_INFLAMMATION                    23     0.73   2.07   5.05E-04
  APPEL_IMATINIB_UP                         29     0.70   2.07   4.94E-04
  MYC_TARGETS                               39     0.65   2.07   4.84E-04
  ADIP_DIFF_CLUSTER4                        31     0.68   2.07   4.99E-04
  CMV_24HRS_UP                              61     0.61   2.06   4.89E-04
  OXIDATIVE_PHOSPHORYLATION                 55     0.61   2.06   5.28E-04
  CMV_ALL_UP                                81     0.57   2.05   6.36E-04
  HOFMANN_MDS_CD34_LOW_AND_HIGH_RISK        31     0.68   2.05   7.14E-04
  FERRANDO_MLL_T\_ALL_DN                    71     0.57   2.03   9.73E-04
  IFNALPHA_NL_UP                            19     0.74   2.01   1.16E-03
  ERM_KO_SERTOLI_DN                         17     0.77   2.01   1.18E-03
  AGED_MOUSE_NEOCORTEX_UP                   60     0.59   2.01   1.16E-03
  INOS_ALL_UP                               47     0.61   2.01   1.16E-03
  CANTHARIDIN_DN                            45     0.61   2.00   1.22E-03
  COLLER_MYC_UP                             17     0.77   2.00   1.43E-03
  ROS_MOUSE_AORTA_DN                        68     0.57   2.00   1.40E-03
  PROTEASOME                                17     0.75   2.00   1.38E-03
  NKTPATHWAY                                28     0.67   1.99   1.53E-03
  HADDAD_CD45CD7_PLUS_VS_MINUS_UP           52     0.58   1.99   1.51E-03
  IL6_FIBRO_UP                              35     0.63   1.99   1.48E-03
  HEARTFAILURE_VENTRICLE_DN                 56     0.59   1.99   1.55E-03
  APOPTOSIS                                 64     0.56   1.98   1.84E-03
  TAKEDA_NUP8_HOXA9_3D_DN                   20     0.71   1.97   1.85E-03
  LIAN_MYELOID_DIFF_GRANULE                 28     0.67   1.96   2.33E-03
  HADDAD_HSC_CD7_UP                         52     0.58   1.96   2.39E-03
  ST_TUMOR_NECROSIS_FACTOR_PATHWAY          28     0.67   1.96   2.56E-03
  MOOTHA_VOXPHOS                            73     0.55   1.95   2.71E-03
  CHAUHAN_2ME2                              42     0.60   1.95   2.76E-03
  RIBOSOMAL_PROTEINS                        78     0.54   1.95   2.77E-03
  TNFALPHA_4HRS_UP                          34     0.63   1.94   2.91E-03
  LEE_MYC_TGFA_UP                           54     0.57   1.94   2.89E-03
  MOREAUX_TACI_HI_IN_PPC_UP                 43     0.59   1.94   2.97E-03
  BHATTACHARYA_ESC_UP                       57     0.57   1.94   3.07E-03
  BRCA_BRCA1_POS                            68     0.56   1.94   3.09E-03
  IFNALPHA_HCC_UP                           23     0.70   1.94   3.13E-03
  DSRNA_UP                                  32     0.64   1.94   3.09E-03
  PROTEASOME_DEGRADATION                    32     0.64   1.93   3.26E-03
  BENNETT_SLE_UP                            19     0.70   1.93   3.39E-03
  TARTE_PC                                  65     0.55   1.93   3.58E-03
  CMV_HCMV_TIMECOURSE_12HRS_UP              21     0.69   1.93   3.58E-03
  TNFALPHA_30MIN_UP                         37     0.61   1.92   3.71E-03
  UVB_NHEK3_C0                              73     0.54   1.92   3.89E-03
  GOLDRATH_CYTOLYTIC                        24     0.67   1.92   3.84E-03
  LIAN_MYELOID_DIFF_RECEPTORS               33     0.61   1.92   3.84E-03
  PARK_RARALPHA_UP                          34     0.61   1.91   4.34E-03
  IL2PATHWAY                                21     0.68   1.90   4.71E-03
  STEMCELL_COMMON_DN                        54     0.56   1.90   4.66E-03
  AGED_MOUSE_CEREBELLUM_UP                  58     0.55   1.89   5.69E-03
  DER_IFNG_UP                               54     0.56   1.88   6.10E-03
  CCR5PATHWAY                               18     0.70   1.87   7.21E-03
  HALMOS_CEBP_UP                            41     0.57   1.86   8.29E-03
  ZHAN_MM_CD138_MF_VS_REST                  30     0.62   1.85   8.56E-03
  HOHENKIRK_MONOCYTE_DEND_UP                85     0.51   1.85   8.52E-03
  ST_GAQ_PATHWAY                            24     0.65   1.85   8.95E-03
  PHOTOSYNTHESIS                            21     0.67   1.85   9.02E-03
  IFN_GAMMA_UP                              35     0.59   1.84   9.97E-03
  IFNA_UV-CMV_COMMON_HCMV_6HRS_UP           20     0.67   1.84   9.88E-03

**Abbreviations:** ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.

###### 

Significantly altered gene sets by A-DEP/saline compared to saline.

  Name                                        Size   ES     NES    FDR q-val
  ------------------------------------------- ------ ------ ------ ------------
  CARIES_PULP_HIGH_UP                         68     0.77   2.89   \<1.00E-06
  LAL_KO_3MO_UP                               46     0.78   2.73   \<1.00E-06
  LAL_KO_6MO_UP                               58     0.73   2.65   \<1.00E-06
  DNA_REPLICATION_REACTOME                    41     0.75   2.55   \<1.00E-06
  ELECTRON_TRANSPORT_CHAIN                    86     0.65   2.55   \<1.00E-06
  CANCER_UNDIFFERENTIATED_META_UP             62     0.69   2.51   \<1.00E-06
  MOOTHA_VOXPHOS                              73     0.67   2.48   \<1.00E-06
  YANG_OSTECLASTS_SIG                         39     0.74   2.45   \<1.00E-06
  MANALO_HYPOXIA_DN                           73     0.65   2.44   \<1.00E-06
  CANCER_NEOPLASTIC_META_UP                   59     0.68   2.44   \<1.00E-06
  YU_CMYC_UP                                  37     0.72   2.38   \<1.00E-06
  GALINDO_ACT_UP                              75     0.62   2.37   \<1.00E-06
  OXIDATIVE_PHOSPHORYLATION                   55     0.66   2.36   \<1.00E-06
  FLECHNER_KIDNEY_TRANSPLANT_REJECTION_UP     72     0.62   2.34   \<1.00E-06
  LINDSTEDT_DEND_8H_VS_48H_UP                 58     0.65   2.32   \<1.00E-06
  CANTHARIDIN_DN                              45     0.66   2.31   \<1.00E-06
  SERUM_FIBROBLAST_CELLCYCLE                  88     0.58   2.30   \<1.00E-06
  FERRANDO_MLL_T\_ALL_DN                      71     0.61   2.30   \<1.00E-06
  SCHUMACHER_MYC_UP                           47     0.66   2.29   \<1.00E-06
  WIELAND_HEPATITIS_B\_INDUCED                71     0.62   2.29   \<1.00E-06
  ADIP_DIFF_CLUSTER4                          31     0.72   2.28   \<1.00E-06
  P21_ANY_DN                                  27     0.74   2.28   \<1.00E-06
  HOUSTIS_ROS                                 32     0.71   2.27   \<1.00E-06
  PEART_HISTONE_DN                            63     0.62   2.27   \<1.00E-06
  IDX_TSA_UP_CLUSTER3                         81     0.60   2.26   4.59E-05
  NEMETH_TNF_UP                               82     0.59   2.25   4.42E-05
  CMV_IE86_UP                                 42     0.67   2.24   4.25E-05
  BLEO_HUMAN_LYMPH_HIGH_24HRS_UP              86     0.57   2.21   4.10E-05
  INOS_ALL_UP                                 47     0.64   2.21   3.96E-05
  MENSSEN_MYC_UP                              30     0.70   2.21   3.83E-05
  UVB_NHEK2_UP                                55     0.61   2.17   2.29E-04
  NI2_MOUSE_UP                                40     0.64   2.16   2.97E-04
  PROTEASOME_DEGRADATION                      32     0.67   2.15   4.35E-04
  RIBOSOMAL_PROTEINS                          78     0.56   2.15   4.57E-04
  BHATTACHARYA_ESC_UP                         57     0.59   2.12   5.44E-04
  HG_PROGERIA_DN                              24     0.71   2.12   5.29E-04
  NAKAJIMA_MCS_UP                             85     0.55   2.12   5.47E-04
  COLLER_MYC_UP                               17     0.76   2.10   6.62E-04
  HEARTFAILURE_VENTRICLE_DN                   56     0.58   2.09   6.74E-04
  OLDAGE_DN                                   45     0.61   2.09   6.58E-04
  BASSO_GERMINAL_CENTER_CD40_UP               82     0.54   2.07   9.37E-04
  DOX_RESIST_GASTRIC_UP                       30     0.65   2.06   1.26E-03
  ZELLER_MYC_UP                               23     0.69   2.04   1.70E-03
  UVB_NHEK1_C1                                41     0.60   2.03   1.69E-03
  MOREAUX_TACI_HI_IN_PPC_UP                   43     0.60   2.03   1.70E-03
  RIBAVIRIN_RSV_UP                            18     0.72   2.01   2.22E-03
  P21_P53_ANY_DN                              35     0.62   2.01   2.17E-03
  BREAST_DUCTAL_CARCINOMA_GENES               19     0.71   2.01   2.30E-03
  CMV_24HRS_UP                                61     0.55   2.00   2.42E-03
  REN_E2F1_TARGETS                            37     0.60   2.00   2.52E-03
  IDX_TSA_UP_CLUSTER5                         82     0.52   2.00   2.49E-03
  CROONQUIST_IL6_STARVE_UP                    32     0.62   1.99   2.51E-03
  TNFALPHA_ALL_UP                             66     0.53   1.99   2.60E-03
  TSA_CD4_UP                                  24     0.65   1.99   2.55E-03
  PYRIMIDINE_METABOLISM                       55     0.55   1.98   2.90E-03
  HINATA_NFKB_UP                              89     0.51   1.97   3.15E-03
  MYC_TARGETS                                 39     0.59   1.96   3.66E-03
  ADIP_DIFF_CLUSTER5                          34     0.59   1.95   4.09E-03
  SHIPP_FL_VS_DLBCL_DN                        30     0.61   1.95   4.06E-03
  TNFA_NFKB_DEP_UP                            17     0.71   1.95   4.23E-03
  ATP_SYNTHESIS                               20     0.67   1.95   4.18E-03
  TNFALPHA_30MIN_UP                           37     0.58   1.95   4.12E-03
  HPV31_DN                                    37     0.58   1.94   4.28E-03
  P21_P53_MIDDLE_DN                           17     0.71   1.94   4.23E-03
  TAVOR_CEBP_UP                               42     0.57   1.93   4.64E-03
  PHOTOSYNTHESIS                              21     0.67   1.93   4.74E-03
  PROTEASOMEPATHWAY                           21     0.65   1.92   5.43E-03
  TARTE_PC                                    65     0.52   1.91   5.70E-03
  TYPE_III_SECRETION_SYSTEM                   20     0.67   1.91   5.66E-03
  CMV_ALL_UP                                  81     0.50   1.91   5.88E-03
  UEDA_MOUSE_SCN                              86     0.49   1.91   5.82E-03
  G1_TO_S\_CELL_CYCLE_REACTOME                65     0.51   1.90   6.40E-03
  STRESS_TPA_SPECIFIC_UP                      34     0.59   1.90   6.36E-03
  CELL_CYCLE                                  71     0.50   1.90   6.42E-03
  FLAGELLAR_ASSEMBLY                          20     0.67   1.89   6.60E-03
  ABBUD_LIF_UP                                45     0.54   1.89   7.01E-03
  KNUDSEN_PMNS_UP                             65     0.51   1.88   7.46E-03
  TPA_SENS_MIDDLE_UP                          55     0.53   1.88   7.62E-03
  CARBON_FIXATION                             18     0.66   1.88   7.67E-03
  MMS_HUMAN_LYMPH_HIGH_24HRS_UP               18     0.69   1.88   7.58E-03
  ZHAN_MM_CD138_PR_VS_REST                    28     0.62   1.87   7.97E-03
  ZUCCHI_EPITHELIAL_DN                        36     0.58   1.87   8.21E-03
  TIS7_OVEREXP_DN                             17     0.67   1.87   8.23E-03
  ZHAN_MULTIPLE_MYELOMA_VS_NORMAL_DN          33     0.58   1.87   8.23E-03
  ROS_MOUSE_AORTA_DN                          68     0.50   1.87   8.17E-03
  BRENTANI_DNA_METHYLATION_AND_MODIFICATION   23     0.63   1.86   8.83E-03
  NADLER_OBESITY_UP                           57     0.52   1.86   8.73E-03
  BLEO_MOUSE_LYMPH_LOW_24HRS_DN               24     0.63   1.86   8.70E-03
  ET743_SARCOMA_UP                            56     0.51   1.86   8.63E-03
  UVB_NHEK3_C6                                25     0.61   1.85   9.32E-03

**Abbreviations:** ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.

###### 

Significantly altered gene sets by C-DEP/saline compared to saline.

  Name                                      Size   ES     NES    FDR q-val
  ----------------------------------------- ------ ------ ------ ------------
  CARIES_PULP_HIGH_UP                       68     0.77   2.90   \<1.00E-06
  GALINDO_ACT_UP                            75     0.72   2.79   \<1.00E-06
  YANG_OSTECLASTS_SIG                       39     0.79   2.74   \<1.00E-06
  LINDSTEDT_DEND_8H_VS_48H_UP               58     0.70   2.69   \<1.00E-06
  HINATA_NFKB_UP                            89     0.65   2.64   \<1.00E-06
  NAKAJIMA_MCS_UP                           85     0.65   2.58   \<1.00E-06
  NEMETH_TNF_UP                             82     0.64   2.57   \<1.00E-06
  LAL_KO_6MO_UP                             58     0.68   2.57   \<1.00E-06
  WIELAND_HEPATITIS_B\_INDUCED              71     0.66   2.53   \<1.00E-06
  LAL_KO_3MO_UP                             46     0.73   2.52   \<1.00E-06
  HOUSTIS_ROS                               32     0.75   2.49   \<1.00E-06
  SANA_TNFA_ENDOTHELIAL_UP                  61     0.66   2.48   \<1.00E-06
  FLECHNER_KIDNEY_TRANSPLANT_REJECTION_UP   72     0.64   2.47   \<1.00E-06
  BLEO_HUMAN_LYMPH_HIGH_24HRS_UP            86     0.61   2.45   \<1.00E-06
  NADLER_OBESITY_UP                         57     0.66   2.45   \<1.00E-06
  ADIP_DIFF_CLUSTER4                        31     0.74   2.44   \<1.00E-06
  MYC_TARGETS                               39     0.71   2.44   \<1.00E-06
  TNFA_NFKB_DEP_UP                          17     0.86   2.42   \<1.00E-06
  NI2_MOUSE_UP                              40     0.71   2.41   \<1.00E-06
  INOS_ALL_UP                               47     0.68   2.39   \<1.00E-06
  TPA_SENS_MIDDLE_UP                        55     0.66   2.38   \<1.00E-06
  TSA_CD4_UP                                24     0.76   2.35   \<1.00E-06
  CANCER_UNDIFFERENTIATED_META_UP           62     0.62   2.35   \<1.00E-06
  ZELLER_MYC_UP                             23     0.76   2.33   \<1.00E-06
  ZUCCHI_EPITHELIAL_DN                      36     0.70   2.33   \<1.00E-06
  CMV_IE86_UP                               42     0.66   2.26   5.58E-05
  CMV_24HRS_UP                              61     0.59   2.26   5.37E-05
  MUNSHI_MM_UP                              57     0.59   2.24   1.03E-04
  DAC_BLADDER_UP                            23     0.74   2.23   1.47E-04
  PASSERINI_INFLAMMATION                    23     0.71   2.19   3.21E-04
  BASSO_GERMINAL_CENTER_CD40_UP             82     0.56   2.19   3.11E-04
  IDX_TSA_UP_CLUSTER3                       81     0.56   2.18   4.32E-04
  MARTINELLI_IFNS_DIFF                      16     0.79   2.18   4.19E-04
  CMV_ALL_UP                                81     0.54   2.17   4.47E-04
  P21_ANY_DN                                27     0.69   2.16   4.73E-04
  MANALO_HYPOXIA_DN                         73     0.55   2.16   4.97E-04
  MUNSHI_MM_VS_PCS_UP                       64     0.58   2.15   5.20E-04
  FERRANDO_MLL_T\_ALL_DN                    71     0.56   2.15   5.06E-04
  SHIPP_FL_VS_DLBCL_DN                      30     0.66   2.14   5.30E-04
  MMS_HUMAN_LYMPH_HIGH_24HRS_UP             18     0.76   2.14   5.16E-04
  DAC_IFN_BLADDER_UP                        16     0.78   2.14   5.37E-04
  DNA_REPLICATION_REACTOME                  41     0.62   2.13   5.24E-04
  PROTEASOME_DEGRADATION                    32     0.66   2.13   5.43E-04
  ROSS_CBF_MYH                              38     0.61   2.12   7.18E-04
  HG_PROGERIA_DN                            24     0.70   2.11   7.33E-04
  ROS_MOUSE_AORTA_DN                        68     0.55   2.10   8.96E-04
  OLDAGE_DN                                 45     0.60   2.09   1.05E-03
  COLLER_MYC_UP                             17     0.76   2.09   1.14E-03
  KNUDSEN_PMNS_UP                           65     0.55   2.08   1.29E-03
  TARTE_PC                                  65     0.54   2.07   1.37E-03
  PROTEASOME                                17     0.75   2.07   1.37E-03
  DER_IFNG_UP                               54     0.56   2.06   1.37E-03
  CANCER_NEOPLASTIC_META_UP                 59     0.55   2.06   1.40E-03
  CHAUHAN_2ME2                              42     0.60   2.06   1.48E-03
  SCHUMACHER_MYC_UP                         47     0.60   2.06   1.45E-03
  UVB_NHEK2_UP                              55     0.57   2.06   1.50E-03
  NKTPATHWAY                                28     0.65   2.06   1.50E-03
  MENSSEN_MYC_UP                            30     0.64   2.06   1.52E-03
  SERUM_FIBROBLAST_CELLCYCLE                88     0.52   2.05   1.54E-03
  TAVOR_CEBP_UP                             42     0.59   2.05   1.58E-03
  PROTEASOMEPATHWAY                         21     0.69   2.04   1.71E-03
  IFNALPHA_NL_UP                            19     0.71   2.04   1.68E-03
  JECHLINGER_EMT_UP                         56     0.55   2.04   1.70E-03
  ABBUD_LIF_UP                              45     0.59   2.04   1.76E-03
  IL6_FIBRO_UP                              35     0.60   2.03   1.79E-03
  PEART_HISTONE_DN                          63     0.53   2.02   2.33E-03
  AS3_FIBRO_DN                              26     0.65   2.01   2.34E-03
  YU_CMYC_UP                                37     0.59   2.01   2.34E-03
  P21_P53_MIDDLE_DN                         17     0.71   2.01   2.31E-03
  STRESS_TPA_SPECIFIC_UP                    34     0.61   2.01   2.40E-03
  DSRNA_UP                                  32     0.60   2.00   2.60E-03
  ERM_KO_SERTOLI_DN                         17     0.71   1.99   2.64E-03
  RADAEVA_IFNA_UP                           38     0.59   1.99   2.73E-03
  TNFALPHA_4HRS_UP                          34     0.60   1.99   2.90E-03
  CANTHARIDIN_DN                            45     0.55   1.98   2.97E-03
  IFN_GAMMA_UP                              35     0.59   1.98   3.04E-03
  HOFMANN_MDS_CD34_LOW_AND_HIGH_RISK        31     0.61   1.97   3.31E-03
  ADIP_DIFF_CLUSTER5                        34     0.59   1.97   3.27E-03
  TIS7_OVEREXP_DN                           17     0.69   1.97   3.22E-03
  LIAN_MYELOID_DIFF_RECEPTORS               33     0.59   1.97   3.36E-03
  MARSHALL_SPLEEN_BAL                       25     0.63   1.95   4.34E-03
  NAKAJIMA_MCSMBP_MAST                      37     0.58   1.94   4.80E-03
  TAKEDA_NUP8_HOXA9_3D_DN                   20     0.67   1.93   5.19E-03
  PYRIMIDINE_METABOLISM                     55     0.52   1.93   5.34E-03
  TNFALPHA_ALL_UP                           66     0.51   1.92   6.17E-03
  CMV_HCMV_TIMECOURSE_12HRS_UP              21     0.65   1.92   6.12E-03
  HEARTFAILURE_VENTRICLE_DN                 56     0.52   1.92   6.14E-03
  IFNALPHA_HCC_UP                           23     0.64   1.91   6.44E-03
  HYPOXIA_REVIEW                            68     0.50   1.91   6.64E-03
  LINDSTEDT_DEND_UP                         44     0.54   1.91   6.87E-03
  CROONQUIST_IL6_RAS_UP                     18     0.67   1.90   7.79E-03
  LEE_MYC_TGFA_UP                           54     0.51   1.89   7.81E-03
  EMT_UP                                    55     0.51   1.89   8.20E-03
  LEE_ACOX1_UP                              58     0.51   1.89   8.21E-03
  BENNETT_SLE_UP                            19     0.65   1.88   8.45E-03
  ZHAN_MMPC_SIMAL                           41     0.55   1.88   8.40E-03
  P21_P53_ANY_DN                            35     0.57   1.88   8.63E-03
  BREAST_DUCTAL_CARCINOMA_GENES             19     0.65   1.88   8.74E-03

**Abbreviations:** ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.

###### 

Significantly altered gene sets by N-DEP/OVA compared to OVA.

  Name                                      Size   ES     NES    FDR q-val
  ----------------------------------------- ------ ------ ------ ------------
  CARIES_PULP_HIGH_UP                       68     0.81   2.76   \<1.00E-06
  LAL_KO_3MO_UP                             46     0.83   2.61   \<1.00E-06
  LAL_KO_6MO_UP                             58     0.79   2.60   \<1.00E-06
  NEMETH_TNF_UP                             82     0.74   2.59   \<1.00E-06
  WIELAND_HEPATITIS_B\_INDUCED              71     0.74   2.54   \<1.00E-06
  NADLER_OBESITY_UP                         57     0.76   2.51   \<1.00E-06
  YANG_OSTECLASTS_SIG                       39     0.82   2.50   \<1.00E-06
  LINDSTEDT_DEND_8H_VS_48H_UP               58     0.73   2.45   \<1.00E-06
  NAKAJIMA_MCS_UP                           85     0.69   2.44   \<1.00E-06
  SANA_TNFA_ENDOTHELIAL_UP                  61     0.71   2.41   \<1.00E-06
  BASSO_GERMINAL_CENTER_CD40_UP             82     0.69   2.40   \<1.00E-06
  GALINDO_ACT_UP                            75     0.69   2.40   \<1.00E-06
  FLECHNER_KIDNEY_TRANSPLANT_REJECTION_UP   72     0.69   2.39   \<1.00E-06
  HINATA_NFKB_UP                            89     0.64   2.26   \<1.00E-06
  NI2_MOUSE_UP                              40     0.70   2.16   3.02E-04
  BLEO_HUMAN_LYMPH_HIGH_24HRS_UP            86     0.60   2.14   2.83E-04
  GOLDRATH_CYTOLYTIC                        24     0.77   2.14   3.32E-04
  BRENTANI_IMMUNE_FUNCTION                  42     0.68   2.13   3.75E-04
  JECHLINGER_EMT_UP                         56     0.64   2.11   5.30E-04
  ADIP_DIFF_CLUSTER3                        28     0.73   2.10   5.03E-04
  TNFA_NFKB_DEP_UP                          17     0.80   2.09   5.83E-04
  YU_CMYC_DN                                53     0.65   2.09   5.57E-04
  YAGI_AML_PROGNOSIS                        31     0.70   2.07   7.26E-04
  ROSS_MLL_FUSION                           60     0.62   2.05   1.12E-03
  LIAN_MYELOID_DIFF_RECEPTORS               33     0.69   2.03   1.47E-03
  EMT_UP                                    55     0.61   2.02   1.50E-03
  PASSERINI_INFLAMMATION                    23     0.74   2.01   1.69E-03
  APPEL_IMATINIB_UP                         29     0.70   2.01   1.96E-03
  ABBUD_LIF_UP                              45     0.64   2.01   1.89E-03
  TAKEDA_NUP8_HOXA9_3D_DN                   20     0.74   2.01   1.86E-03
  LINDSTEDT_DEND_DN                         53     0.61   2.01   1.87E-03
  CMV_ALL_UP                                81     0.56   2.01   1.81E-03
  TAVOR_CEBP_UP                             42     0.63   1.99   2.34E-03
  STEMCELL_COMMON_DN                        54     0.60   1.98   2.89E-03
  SCHUMACHER_MYC_UP                         47     0.61   1.97   3.54E-03
  ERM_KO_SERTOLI_DN                         17     0.75   1.96   3.66E-03
  DAC_IFN_BLADDER_UP                        16     0.77   1.95   4.26E-03
  SANA_IFNG_ENDOTHELIAL_UP                  45     0.62   1.95   4.26E-03
  WANG_HOXA9_VS_MEIS1_UP                    25     0.68   1.94   4.75E-03
  LIAN_MYELOID_DIFF_GRANULE                 28     0.68   1.93   5.19E-03
  CMV_24HRS_UP                              61     0.58   1.93   5.58E-03
  MARTINELLI_IFNS_DIFF                      16     0.75   1.93   5.45E-03
  TARTE_PC                                  65     0.56   1.92   5.48E-03
  MYC_TARGETS                               39     0.63   1.92   5.46E-03
  WANG_MLL_CBP_VS_GMP_UP                    42     0.61   1.91   6.10E-03
  XU_CBP_UP                                 25     0.68   1.91   6.53E-03
  LOTEM_LEUKEMIA_UP                         22     0.69   1.91   6.39E-03
  LINDSTEDT_DEND_UP                         44     0.61   1.90   6.60E-03
  LU_IL4BCELL                               62     0.56   1.90   6.79E-03
  ZELLER_MYC_UP                             23     0.69   1.90   6.99E-03
  CASPASEPATHWAY                            20     0.69   1.90   6.89E-03
  ROSS_CBF_MYH                              38     0.62   1.90   6.76E-03
  CMV_8HRS_UP                               27     0.66   1.88   8.38E-03
  TPA_SENS_MIDDLE_UP                        55     0.57   1.88   8.27E-03
  DSRNA_UP                                  32     0.63   1.87   8.52E-03
  NAKAJIMA_MCSMBP_MAST                      37     0.61   1.87   8.37E-03
  CROONQUIST_IL6_RAS_UP                     18     0.72   1.87   8.38E-03
  GENOTOXINS_ALL_24HRS_REG                  22     0.68   1.87   8.26E-03
  HOHENKIRK_MONOCYTE_DEND_UP                85     0.53   1.87   8.40E-03
  SHIPP_FL_VS_DLBCL_DN                      30     0.63   1.87   8.34E-03

**Abbreviations:** ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.

###### 

Significantly altered gene sets by A-DEP/OVA compared to OVA.

  Name                                      Size   ES     NES    FDR q-val
  ----------------------------------------- ------ ------ ------ ------------
  YANG_OSTECLASTS_SIG                       39     0.86   2.84   \<1.00E-06
  LAL_KO_6MO_UP                             58     0.74   2.59   \<1.00E-06
  NAKAJIMA_MCS_UP                           85     0.68   2.58   \<1.00E-06
  LINDSTEDT_DEND_8H_VS_48H_UP               58     0.73   2.58   \<1.00E-06
  LAL_KO_3MO_UP                             46     0.76   2.56   \<1.00E-06
  NADLER_OBESITY_UP                         57     0.72   2.56   \<1.00E-06
  GALINDO_ACT_UP                            75     0.70   2.54   \<1.00E-06
  SANA_TNFA_ENDOTHELIAL_UP                  61     0.71   2.52   \<1.00E-06
  CARIES_PULP_HIGH_UP                       68     0.70   2.50   \<1.00E-06
  NEMETH_TNF_UP                             82     0.66   2.43   \<1.00E-06
  JECHLINGER_EMT_UP                         56     0.67   2.32   \<1.00E-06
  HINATA_NFKB_UP                            89     0.60   2.29   \<1.00E-06
  TNFA_NFKB_DEP_UP                          17     0.85   2.29   \<1.00E-06
  NI2_MOUSE_UP                              40     0.70   2.26   7.14E-05
  ERM_KO_SERTOLI_DN                         17     0.83   2.25   6.67E-05
  BASSO_GERMINAL_CENTER_CD40_UP             82     0.61   2.24   6.25E-05
  WIELAND_HEPATITIS_B\_INDUCED              71     0.62   2.22   5.88E-05
  EMT_UP                                    55     0.63   2.21   5.56E-05
  PASSERINI_INFLAMMATION                    23     0.75   2.19   5.26E-05
  NAKAJIMA_MCSMBP_MAST                      37     0.68   2.17   5.00E-05
  TPA_SENS_MIDDLE_UP                        55     0.62   2.16   4.76E-05
  LIAN_MYELOID_DIFF_RECEPTORS               33     0.69   2.14   1.40E-04
  BENNETT_SLE_UP                            19     0.77   2.13   2.24E-04
  TGFBETA_C2_UP                             17     0.79   2.12   2.14E-04
  TAKEDA_NUP8_HOXA9_3D_DN                   20     0.76   2.12   2.48E-04
  RADAEVA_IFNA_UP                           38     0.65   2.10   3.19E-04
  IL1_CORNEA_UP                             53     0.60   2.08   5.72E-04
  DAC_BLADDER_UP                            23     0.72   2.08   5.89E-04
  DAC_IFN_BLADDER_UP                        16     0.79   2.08   6.03E-04
  MARTINELLI_IFNS_DIFF                      16     0.77   2.07   6.89E-04
  TAVOR_CEBP_UP                             42     0.62   2.06   7.32E-04
  AS3_FIBRO_DN                              26     0.70   2.05   7.74E-04
  HEARTFAILURE_VENTRICLE_DN                 56     0.59   2.03   1.03E-03
  CANCER_UNDIFFERENTIATED_META_UP           62     0.56   2.01   1.43E-03
  FLECHNER_KIDNEY_TRANSPLANT_REJECTION_UP   72     0.55   2.01   1.39E-03
  ADIP_DIFF_CLUSTER4                        31     0.64   2.01   1.38E-03
  KNUDSEN_PMNS_UP                           65     0.56   2.00   1.39E-03
  AGED_MOUSE_CEREBELLUM_UP                  58     0.58   1.99   1.66E-03
  CMV_ALL_UP                                81     0.54   1.98   1.90E-03
  BLEO_HUMAN_LYMPH_HIGH_24HRS_UP            86     0.52   1.98   2.06E-03
  MATRIX_METALLOPROTEINASES                 24     0.69   1.98   2.04E-03
  DORSEY_DOXYCYCLINE_UP                     23     0.68   1.96   2.53E-03
  PASSERINI_EM                              34     0.62   1.96   2.56E-03
  TSA_CD4_UP                                24     0.66   1.95   2.62E-03
  CROONQUIST_IL6_RAS_UP                     18     0.70   1.95   2.70E-03
  ZUCCHI_EPITHELIAL_DN                      36     0.60   1.94   3.52E-03
  CMV_8HRS_UP                               27     0.64   1.93   4.18E-03
  IFNALPHA_HCC_UP                           23     0.66   1.92   4.21E-03
  SANA_IFNG_ENDOTHELIAL_UP                  45     0.58   1.92   4.35E-03
  APPEL_IMATINIB_UP                         29     0.63   1.92   4.30E-03
  SHEPARD_POS_REG_OF_CELL_PROLIFERATION     85     0.52   1.92   4.22E-03
  CROONQUIST_IL6_STROMA_UP                  34     0.60   1.92   4.34E-03
  SERUM_FIBROBLAST_CELLCYCLE                88     0.50   1.91   4.61E-03
  DSRNA_UP                                  32     0.61   1.91   4.91E-03
  MYC_TARGETS                               39     0.58   1.90   5.89E-03
  INSULIN_NIH3T3_UP                         15     0.72   1.89   6.12E-03
  CHAUHAN_2ME2                              42     0.56   1.89   6.17E-03
  CAMPTOTHECIN_PROBCELL_DN                  21     0.66   1.89   6.08E-03
  LINDSTEDT_DEND_DN                         53     0.55   1.89   6.21E-03
  LEE_DENA_UP                               55     0.54   1.88   6.31E-03
  ROSS_MLL_FUSION                           60     0.53   1.88   6.51E-03
  CCR5PATHWAY                               18     0.68   1.88   6.64E-03
  PEART_HISTONE_DN                          63     0.52   1.88   6.61E-03
  IRITANI_ADPROX_DN                         45     0.55   1.87   7.03E-03
  ABBUD_LIF_UP                              45     0.56   1.87   7.16E-03
  MUNSHI_MM_UP                              57     0.53   1.87   7.10E-03
  ZHAN_MULTIPLE_MYELOMA_VS_NORMAL_DN        33     0.61   1.87   7.10E-03
  NKTPATHWAY                                28     0.62   1.85   9.28E-03

**Abbreviations:** ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.

###### 

Significantly altered gene sets by C-DEP/OVA compared to OVA.

  Name                                      Size   ES     NES    FDR q-val
  ----------------------------------------- ------ ------ ------ ------------
  CARIES_PULP_HIGH_UP                       68     0.80   2.94   \<1.00E-06
  WIELAND_HEPATITIS_B\_INDUCED              71     0.76   2.83   \<1.00E-06
  NEMETH_TNF_UP                             82     0.73   2.77   \<1.00E-06
  YANG_OSTECLASTS_SIG                       39     0.82   2.73   \<1.00E-06
  LINDSTEDT_DEND_8H_VS_48H_UP               58     0.76   2.73   \<1.00E-06
  FLECHNER_KIDNEY_TRANSPLANT_REJECTION_UP   72     0.73   2.71   \<1.00E-06
  IFNA_HCMV_6HRS_UP                         38     0.80   2.64   \<1.00E-06
  LAL_KO_6MO_UP                             58     0.76   2.64   \<1.00E-06
  GALINDO_ACT_UP                            75     0.71   2.62   \<1.00E-06
  LAL_KO_3MO_UP                             46     0.77   2.60   \<1.00E-06
  SANA_TNFA_ENDOTHELIAL_UP                  61     0.73   2.59   \<1.00E-06
  CMV_ALL_UP                                81     0.67   2.50   \<1.00E-06
  SANA_IFNG_ENDOTHELIAL_UP                  45     0.74   2.50   \<1.00E-06
  RADAEVA_IFNA_UP                           38     0.76   2.49   \<1.00E-06
  CMV_8HRS_UP                               27     0.81   2.48   \<1.00E-06
  BASSO_GERMINAL_CENTER_CD40_UP             82     0.66   2.48   \<1.00E-06
  NAKAJIMA_MCS_UP                           85     0.65   2.46   \<1.00E-06
  DER_IFNA_UP                               53     0.69   2.45   \<1.00E-06
  CANCER_NEOPLASTIC_META_UP                 59     0.69   2.45   \<1.00E-06
  DER_IFNB_UP                               76     0.65   2.41   \<1.00E-06
  HINATA_NFKB_UP                            89     0.63   2.41   \<1.00E-06
  CMV_HCMV_TIMECOURSE_12HRS_UP              21     0.82   2.39   \<1.00E-06
  CANCER_UNDIFFERENTIATED_META_UP           62     0.66   2.34   \<1.00E-06
  CMV_24HRS_UP                              61     0.66   2.34   \<1.00E-06
  MANALO_HYPOXIA_DN                         73     0.62   2.33   \<1.00E-06
  NADLER_OBESITY_UP                         57     0.66   2.32   \<1.00E-06
  IFNA_UV-CMV_COMMON_HCMV_6HRS_UP           20     0.81   2.32   \<1.00E-06
  SCHUMACHER_MYC_UP                         47     0.68   2.32   \<1.00E-06
  DER_IFNG_UP                               54     0.66   2.28   \<1.00E-06
  IFN_ANY_UP                                71     0.61   2.27   \<1.00E-06
  PEART_HISTONE_DN                          63     0.63   2.26   \<1.00E-06
  IFN_BETA_UP                               55     0.64   2.26   \<1.00E-06
  ADIP_DIFF_CLUSTER4                        31     0.72   2.25   \<1.00E-06
  IFNALPHA_NL_UP                            19     0.80   2.25   \<1.00E-06
  IFN_GAMMA_UP                              35     0.69   2.23   \<1.00E-06
  GOLDRATH_CYTOLYTIC                        24     0.75   2.21   \<1.00E-06
  IFNALPHA_HCC_UP                           23     0.74   2.20   \<1.00E-06
  CANTHARIDIN_DN                            45     0.65   2.20   \<1.00E-06
  MOREAUX_TACI_HI_IN_PPC_UP                 43     0.66   2.19   \<1.00E-06
  DAC_IFN_BLADDER_UP                        16     0.82   2.19   \<1.00E-06
  BENNETT_SLE_UP                            19     0.79   2.18   \<1.00E-06
  STRESS_TPA_SPECIFIC_UP                    34     0.69   2.17   2.91E-05
  TNFA_NFKB_DEP_UP                          17     0.81   2.17   2.84E-05
  TARTE_PC                                  65     0.60   2.17   2.77E-05
  BLEO_HUMAN_LYMPH_HIGH_24HRS_UP            86     0.57   2.17   2.71E-05
  DSRNA_UP                                  32     0.69   2.16   2.65E-05
  TSA_CD4_UP                                24     0.73   2.15   5.32E-05
  JECHLINGER_EMT_UP                         56     0.61   2.14   1.30E-04
  INOS_ALL_UP                               47     0.62   2.14   1.27E-04
  IFN_ALL_UP                                16     0.79   2.14   1.25E-04
  IFN_ALPHA_UP                              34     0.67   2.13   1.95E-04
  LIAN_MYELOID_DIFF_RECEPTORS               33     0.67   2.13   1.91E-04
  BRCA_BRCA1_POS                            68     0.58   2.13   2.11E-04
  ERM_KO_SERTOLI_DN                         17     0.78   2.12   2.07E-04
  COLLER_MYC_UP                             17     0.78   2.12   2.03E-04
  AMINOACYL_TRNA_BIOSYNTHESIS               18     0.75   2.10   4.86E-04
  PROTEASOMEPATHWAY                         21     0.73   2.09   5.20E-04
  HSC_INTERMEDIATEPROGENITORS_ADULT         88     0.54   2.09   5.11E-04
  PASSERINI_INFLAMMATION                    23     0.70   2.08   6.52E-04
  LINDSTEDT_DEND_DN                         53     0.59   2.07   6.83E-04
  ROSS_CBF_MYH                              38     0.63   2.07   7.52E-04
  LU_IL4BCELL                               62     0.57   2.06   7.81E-04
  DNA_REPLICATION_REACTOME                  41     0.64   2.06   7.68E-04
  STRESS_GENOTOXIC_SPECIFIC_DN              36     0.63   2.06   9.11E-04
  SERUM_FIBROBLAST_CELLCYCLE                88     0.54   2.05   9.35E-04
  YAGI_AML_PROGNOSIS                        31     0.65   2.05   9.21E-04
  EMT_UP                                    55     0.58   2.05   9.07E-04
  PROTEASOME_DEGRADATION                    32     0.65   2.05   9.12E-04
  NI2_MOUSE_UP                              40     0.62   2.05   9.88E-04
  HSC_INTERMEDIATEPROGENITORS_SHARED        80     0.54   2.05   9.74E-04
  LINDSTEDT_DEND_UP                         44     0.61   2.04   1.05E-03
  TRNA_SYNTHETASES                          17     0.75   2.03   1.19E-03
  SHIPP_FL_VS_DLBCL_DN                      30     0.66   2.02   1.29E-03
  INSULIN_ADIP_INSENS_UP                    17     0.73   2.02   1.36E-03
  PROTEASOME                                17     0.74   2.01   1.46E-03
  GOLDRATH_CELLCYCLE                        28     0.65   2.01   1.52E-03
  ZHAN_MULTIPLE_MYELOMA_SUBCLASSES_DIFF     26     0.67   2.01   1.68E-03
  YU_CMYC_DN                                53     0.58   2.00   1.72E-03
  UV-CMV_UNIQUE_HCMV_6HRS_UP                83     0.53   2.00   1.72E-03
  CHOLESTEROL_BIOSYNTHESIS                  15     0.76   2.00   1.69E-03
  TAKEDA_NUP8_HOXA9_3D_DN                   20     0.70   2.00   1.69E-03
  YU_CMYC_UP                                37     0.61   1.99   1.77E-03
  UEDA_MOUSE_SCN                            86     0.53   1.98   2.20E-03
  APOPTOSIS                                 64     0.55   1.98   2.34E-03
  ZELLER_MYC_UP                             23     0.68   1.96   3.06E-03
  DAC_BLADDER_UP                            23     0.67   1.96   3.11E-03
  MYC_TARGETS                               39     0.58   1.94   3.99E-03
  BLEO_MOUSE_LYMPH_HIGH_24HRS_DN            32     0.62   1.94   3.97E-03
  CMV_HCMV_6HRS_UP                          19     0.70   1.94   3.99E-03
  HDACI_COLON_CUR24HRS_UP                   28     0.63   1.94   3.96E-03
  UNDERHILL_PROLIFERATION                   18     0.69   1.93   4.03E-03
  MENSSEN_MYC_UP                            30     0.63   1.93   4.16E-03
  IL1_CORNEA_UP                             53     0.55   1.93   4.15E-03
  FASPATHWAY                                25     0.65   1.93   4.18E-03
  MUNSHI_MM_UP                              57     0.54   1.92   5.04E-03
  IDX_TSA_UP_CLUSTER3                       81     0.51   1.92   5.09E-03
  ST_TUMOR_NECROSIS_FACTOR_PATHWAY          28     0.64   1.91   5.10E-03
  PYRIMIDINE_METABOLISM                     55     0.54   1.91   5.39E-03
  KNUDSEN_PMNS_UP                           65     0.53   1.91   5.40E-03
  NFKBPATHWAY                               23     0.65   1.90   5.53E-03
  HEARTFAILURE_VENTRICLE_DN                 56     0.53   1.90   5.62E-03
  CMV_UV-CMV_COMMON_HCMV_6HRS_UP            17     0.70   1.90   6.00E-03
  ABBUD_LIF_UP                              45     0.56   1.88   7.06E-03
  HPV31_DN                                  37     0.57   1.88   7.03E-03
  LOTEM_LEUKEMIA_UP                         22     0.65   1.88   7.17E-03
  TPA_SENS_MIDDLE_UP                        55     0.54   1.88   7.59E-03
  CASPASEPATHWAY                            20     0.67   1.88   7.62E-03
  UVC_HIGH_D3_DN                            35     0.59   1.87   7.75E-03
  WANG_MLL_CBP_VS_GMP_UP                    42     0.56   1.87   8.33E-03
  MARSHALL_SPLEEN_BAL                       25     0.62   1.86   9.11E-03
  XU_CBP_UP                                 25     0.61   1.86   9.64E-03
  MUNSHI_MM_VS_PCS_UP                       64     0.51   1.86   9.70E-03
  GENOTOXINS_ALL_24HRS_REG                  22     0.64   1.86   9.65E-03

**Abbreviations:** ES, enrichment score; NES, normalized enrichment score; FDR, false discovery rate.

![Principle component analysis (PCA) plot from microarray data. PCA plots were created in Rosetta Resolver. Each plot is a representation of all gene chip samples (8 treatments, n = 3) and each dot represents all the genes from one gene chip. Gene chips were highlighted according to the immunization protocol (**A**) (blue-OVA treatment or red-saline treatment) or the diesel exposure (**B**) (yellow- saline and saline/OVA, pink- A-DEP and A-DEP/OVA, blue- C-DEP/saline and C-DEP/OVA, and green- N-DEP/saline and N-DEP/OVA).](bii-3-2010-029f1){#f1-bii-3-2010-029}

![Venn analyses. Venn analyses of the core genes extracted from significantly altered gene sets in GSEA associated with A-, C-, and N-DEP/saline exposures (**A**) and A-, C-, N-DEP/OVA exposurse (**B**). Venn analysis of the common genes associated with all DEP/saline and DEP/OVA exposures (**C**).](bii-3-2010-029f2){#f2-bii-3-2010-029}

![Results of GeneGo mapping of differentially affected networks. The core genes from significantly altered gene sets associated with each DEP/OVA exposure (N-DEP/OVA-blue; A-DEP/OVA-red; C-DEP/OVA-orange) was imported into GeneGo to generate a list of the top 20 networks.](bii-3-2010-029f3){#f3-bii-3-2010-029}

![Results of GeneGo mapping of differentially affected pathways. The core genes from significantly altered gene sets associated with each DEP/OVA exposure (N-DEP/OVA-blue; A-DEP/OVA-red; C-DEP/OVA-orange) was imported into GeneGo to generate a list of the top 20 pathways.](bii-3-2010-029f4){#f4-bii-3-2010-029}

###### 

KEGG pathways mapped from the 200 common genes associated with DEP/saline exposure.

  KEGG pathway                                                       \# Genes   *P* value
  ------------------------------------------------------------------ ---------- -----------
  Cytokine-cytokine receptor interaction                             28         \<0.0001
   Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1 Ccr2 Csf2                
   Csf2rb1 Cxcl1 Cxcl10 Cxcl13 Cxcl2 Cxcl5 Ifngr2 Il1b Il1r2 Il8rb              
   Inhba Ltb Osmr Tnf Tnfrsf1b Tnfrsf9                                          
  Toll-like receptor signaling pathway                               11         \<0.0001
   Ccl3 Ccl4 Cd14 Cxcl10 Il1b Nfkb2 Nfkbia Pik3cd Rac2 Tlr2 Tnf                 

###### 

KEGG pathways mapped from the 236 genes common to all DEP/OVA exposure.

  KEGG pathway                                                             \# Genes   *P* value
  ------------------------------------------------------------------------ ---------- -----------
  Cytokine-cytokine receptor interaction                                   40         \<0.0001
   Ccl11 Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1 Ccr2                     
   Ccr5 Csf1 Csf2 Csf2ra Csf2rb1 Csf2rb2 Csf3r Cxcl1 Cxcl10 Cxcl11                    
   Cxcl13 Cxcl2 Cxcl5 Cxcl9 Ifngr2 Il1a Il1b Il1r1 Il1r2 Il2rg Il6 Il8rb              
   Osmr Tgfb1 Tnf Tnfrsf1b Tnfrsf5 Tnfrsf9                                            
  Toll-like receptor signaling pathway                                     17         \<0.0001
   Ccl3 Ccl4 Cd14 Cxcl10 Cxcl11 Cxcl9 Ikbke Il1b Il6 Lbp Nfkb1                        
   Nfkb2 Pik3cd Rac2 Stat1 Tlr2 Tnf                                                   
  Apoptosis                                                                11         0.0002
   Birc3 Cflar Csf2rb1 Csf2rb2 Il1a Il1b Il1r1 Nfkb1 Nfkb2 Pik3cd Tnf                 

###### 

KEGG pathways mapped from the 117 genes common to both DEP/OVA and DEP/saline exposure.

  KEGG pathway                                                       \# Genes   *P* value
  ------------------------------------------------------------------ ---------- -----------
  Cytokine-cytokine receptor interaction                             26         \<0.0001
   Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1 Ccr2 Csf2                
   Csf2rb1 Cxcl1 Cxcl10 Cxcl13 Cxcl2 Cxcl5 Ifngr2 Il1b Il1r2 Il8rb              
   Osmr Tnf Tnfrsf1b Tnfrsf9                                                    
  Toll-like receptor signaling pathway                               10         \<0.0001
   Ccl3 Ccl4 Cd14 Cxcl10 Il1b Nfkb2 Pik3cd Rac2 Tlr2 Tnf                        

###### 

KEGG pathway mapped from the 526 genes associated with N-DEP/OVA exposure.

  KEGG pathway                                                               \# Genes   *P* value
  -------------------------------------------------------------------------- ---------- -----------
  Cytokine-cytokine receptor interaction                                     56         \<0.0001
   Ccl11 Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1                            
   Ccr2 Ccr5 Ccr6 Ccr7 Csf1 Csf1r Csf2 Csf2ra Csf2rb1 Csf2rb2                           
   Csf3r Cxcl1 Cxcl10 Cxcl11 Cxcl13 Cxcl2 Cxcl5 Cxcl9 Ifnar1                            
   Ifnar2 Ifngr2 Il10ra Il15 Il18rap Il1a Il1b Il1r1 Il1r2 Il2 Il2ra Il2rg              
   Il3ra Il6 Il7r Il8rb Ltb Osmr Tgfb1 Tnf Tnfrsf10b Tnfrsf13c                          
   Tnfrsf1b Tnfrsf5 Tnfrsf9 Tnfsf9                                                      
  Toll-like receptor signaling pathway                                       23         \<0.0001
   Ccl3 Ccl4 Cd14 Cd86 Cxcl10 Cxcl11 Cxcl9 Fos Ifnar1 Ifnar2                            
   Ikbke Il1b Il6 Lbp Nfkb1 Nfkb2 Nfkbia Pik3cd Rac2 Stat1 Tlr2                         
   Tlr7 Tnf                                                                             
  Neuroactive ligand-receptor interaction                                    6          0.0002
   Adora2b C3ar1 Ctsg Fpr1 P2ry6 Ptger4                                                 

###### 

KEGG pathways mapped from the 483 genes associated with A-DEP/OVA exposure.

  KEGG pathway                                                             \# Genes   *P* value
  ------------------------------------------------------------------------ ---------- -----------
  Cytokine-cytokine receptor interaction                                   56         \<0.0001
   Ccl11 Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1 Ccr2                     
   Ccr4 Ccr5 Csf1 Csf2 Csf2ra Csf2rb1 Csf2rb2 Csf3r Cxcl1 Cxcl10                      
   Cxcl11 Cxcl13 Cxcl2 Cxcl5 Cxcl9 Ifnar2 Ifnb1 Ifng Ifngr2 Il12a                     
   Il12b Il12rb1 Il1a Il1b Il1r1 Il1r2 Il2 Il2rg Il4 Il5 Il6 Il8rb Inhba              
   Osmr Tgfb1 Tgfbr1 Tnf Tnfrsf1a Tnfrsf1b Tnfrsf5 Tnfrsf9 Tnfsf10                    
   Tnfsf13 Tnfsf13b                                                                   
  Toll-like receptor signaling pathway                                     26         \<0.0001
   Ccl3 Ccl4 Cd14 Cxcl10 Cxcl11 Cxcl9 Ifnar2 Ifnb1 Ikbke Il12a Il12b                  
   Il1b Il6 Lbp Map3k7ip1 Mapk13 Myd88 Nfkb1 Nfkb2 Nfkbia                             
   Pik3cd Rac2 Stat1 Tlr1 Tlr2 Tnf                                                    
  Apoptosis                                                                19         \<0.0001
   Bax Birc3 Capn1 Casp3 Cflar Csf2rb1 Csf2rb2 Il1a Il1b Il1r1                        
   Myd88 Nfkb1 Nfkb2 Nfkbia Pik3cd Ripk1 Tnf Tnfrsf1a Tnfsf10                         

###### 

KEGG pathways mapped from the 800 genes associated with C-DEP/OVA exposure.

  KEGG pathway                                                          \# Genes   *P* value
  --------------------------------------------------------------------- ---------- -----------
  Apoptosis                                                             28         \<0.0001
   Apaf1 Bax Bid Birc2 Birc3 Casp3 Casp7 Casp8 Cflar Chuk                          
   Csf2rb1 Csf2rb2 Dffa Ikbkb Il1a Il1b Il1r1 Il3ra Irak1 Myd88                    
   Nfkb1 Nfkb2 Pik3cd Ripk1 Tnf Tnfrsf1a Tradd Traf2                               
  Cytokine-cytokine receptor interaction                                51         \<0.0001
   Ccl11 Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1                       
   Ccr2 Ccr5 Csf1 Csf2 Csf2ra Csf2rb1 Csf2rb2 Csf3r Cxcl1 Cxcl10                   
   Cxcl11 Cxcl13 Cxcl2 Cxcl5 Cxcl9 Ifngr2 Il10ra Il1a Il1b Il1r1                   
   Il1r2 Il2rb Il2rg Il3ra Il6 Il7r Il8rb Inhba Ltb Osmr Tgfb1 Tgfbr1              
   Tnf Tnfrsf1a Tnfrsf1b Tnfrsf25 Tnfrsf5 Tnfrsf9 Tnfsf13b Tnfsf9                  
  Aminoacyl-tRNA biosynthesis                                           13         \<0.0001
   Aars Cars Fars1 Farslb Gars Iars Kars Nars Rars Tars Vars2                      
   Wars Yars                                                                       
  Toll-like receptor signaling pathway                                  28         \<0.0001
   Casp8 Ccl3 Ccl4 Cd14 Chuk Cxcl10 Cxcl11 Cxcl9 Ikbkb Ikbke                       
   Il1b Il6 Irak1 Lbp Ly96 Map2k4 Map3k7 Mapk13 Myd88 Nfkb1                        
   Nfkb2 Pik3cd Rac2 Stat1 Tlr2 Tlr4 Tlr7 Tnf                                      
  Pyrimidine metabolism                                                 21         \<0.0001
   Ctps Dck Dtymk Dut Ecgf1 Nme1 Nme2 Pola2 Pold1                                  
   Pold2 Pole2 Polr2 g Polr2h Polr3k Prim1 Rrm2 Txnrd1 Umpk                        
   Umps Upp1                                                                       
  Neuroactive ligand-receptor interaction                               7          \<0.0001
   Adora2b Bzrp C3ar1 Grik5 Gzma P2ry6 Ptger4                                      
